Evidence map›Paper›PMID 37621732›Full record

ArticleBulletin of Japan Society of Coordination Chemistry2022

Engineered Myoglobin Catalysts for Asymmetric Intermolecular Cyclopropanation Reactions.

Mary G Siriboe, Rudi Fasan

Open access · diamondAbstract read
In one paragraph

Article in Bulletin of Japan Society of Coordination Chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mary G SiriboeDepartment of Chemistry, University of Rochester, Rochester, New York 14627, United States.
Rudi FasanDepartment of Chemistry, University of Rochester, Rochester, New York 14627, United States.
University of Rochester · US

Funding

Selective P450 Oxidation Catalysts for Synthesis of Bioactive MoleculesR01GM098628 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI FASAN, RUDI · 2012 to 2024
$4.7M
NIH Training Grant in Chemistry-Biology InterfaceT32GM145461 · NIGMS · UNIVERSITY OF ROCHESTER · PI KARA L. BREN, Bradley L. Nilsson · 2022 to 2026
$988k
NIH Training Grant in the Chemistry-Biology InterfaceT32GM118283 · NIGMS · UNIVERSITY OF ROCHESTER · PI BREN, KARA L., FASAN, RUDI · 2017 to 2021
$850k
NIGMS NIH HHS R01 GM098628NIGMS NIH HHS T32 GM118283NIGMS NIH HHS T32 GM145461
6 · The paper itself

Abstract

Biocatalysis has covered an increasingly important role in the synthesis and manufacturing of pharmaceuticals and other high value compounds. In the interest of expanding the range of synthetically useful reactions accessible via biocatalysts, our group has explored the potential and application of engineered myoglobins for 'abiological' carbene transfer catalysis. These transformations provide a direct route for the construction of new carbon-carbon and carbon-heteroatom bonds, including the synthesis of cyclopropane rings, which are key motifs and pharmacophores in many drugs and bioactive natural products. In this award article, we survey the progress made by our group toward the development of myoglobin-based catalysts for asymmetric intermolecular cyclopropanation reactions. The high stereoselectivity exhibited by these biocatalysts in these reactions, combined with their broad substrate scope, scalability, and robustness to high substrate loading and organic co-solvents, contribute to make these systems particularly useful for chemical synthesis and biocatalysis at the preparative scale. Extension of the scope of biocatalytic carbene transfer reactions to include different classes of carbene donor reagents has created new opportunities for the asymmetric synthesis of functionalized cyclopropanes. Furthermore, the integration of myoglobin-catalyzed stereoselective cyclopropanations with chemical diversification of the enzymatic products has furnished attractive chemoenzymatic strategies to access a diverse range of optically active cyclopropane scaffolds of high value for drug discovery, medicinal chemistry, and the synthesis of natural products.

Identifiers

PMID37621732
PMCPMC10448740
OpenAlexW4317033207

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.